Candel Therapeutics, Inc. (CADL) Misses Q2 EPS by 29c

Candel Therapeutics, Inc. (NASDAQ: CADL) reported Q2 EPS of ($0.52), $0.29 worse than the analyst estimate of ($0.23).

For earnings history and earnings-related data on Candel Therapeutics, Inc. (CADL) click here.

You May Also Be Interested In

• Blackhawk Network (HAWK) Reports Q2 Loss of $0.07; Offers Guidance
• 4D Molecular Therapeutics, Inc. (FDMT) Misses Q2 EPS by 3c
• The Elmet Group Co. (ELMT) Reports Q2 EPS of $0.18